MethodologyAbout
Search
Menu
US · NYSE LLY

Eli Lilly (LLY) financial statements: income, balance sheet and cash flow

NYSE: LLY · Health care · United States

Signed off by OffScriptBySami on  · Updated

Data as of  · For information only, not investment advice.

In brief

Eli Lilly (NYSE: LLY) reported net income of USD 7.10 billion for Q2 2026 and total assets of USD 142 billion at 30 Jun 2026, according to its Form 10-Q. At 30 Jun 2026 total debt was USD 54.9 billion and cash and short-term investments USD 8.95 billion, so net debt, our calculation, was USD 46.0 billion.

Data as of Source: Form 10-Q for Q2 2026, filed

Key facts

Data as of

Eli Lilly (NYSE: LLY) · USD · fiscal year ends 31 December · figures from SEC filings; derived values are marked.

Revenue, TTM (USD bn)
79.7
TTM to · derived
Revenue by quarter, from USD 11.4 bn in Q3 2024 to USD 23.0 bn in Q2 2026
Operating income, TTM (USD)
Not presented
no such subtotal in the company's statements; we do not build one
Net income, TTM (USD bn)
26.7
TTM to · derived
Free cash flow, TTM (USD bn)
18.2
TTM to · derived
Total assets (USD bn)
142
at · Form 10-Q
Net debt (USD bn)
46.0
at · derived: total debt minus cash and short-term investments

What the numbers show

Eli Lilly's income statement for Q2 FY2026, the quarter ended 30 Jun 2026, shows revenue of USD 23.0 billion, up 47.7% on Q2 FY2025. Net income was USD 7.10 billion, a net margin of 30.9%, our calculation. Gross margin, also ours, was 85.8%, against 84.3% a year earlier.

Revenue grew from USD 28.3 billion in FY2021 to USD 65.2 billion in FY2025, a compound annual growth rate of 23.2%, our calculation. Net income grew 38.7% a year over that run, faster than revenue, and net margin went from 19.7% to 31.7%. Eli Lilly's income statement has no operating income line, so there is no operating margin. Cells marked R were restated in a later filing, and the tables print the restated value.

Eli Lilly's balance sheet held total assets of USD 142 billion at 30 Jun 2026, against USD 117 billion at 31 Mar 2026. Goodwill and intangibles were USD 27.0 billion, up from USD 13.5 billion at the end of Q1. Inventory was USD 16.8 billion. Equity was USD 33.9 billion, and current assets of USD 64.7 billion exceeded current liabilities of USD 47.7 billion.

Total debt, the sum of short-term and long-term borrowings, was USD 54.9 billion at 30 Jun 2026, against USD 43.4 billion at 31 Mar 2026. With cash and short-term investments of USD 8.95 billion, net debt was USD 46.0 billion, our calculation. At the year-ends, total debt went from USD 16.9 billion in FY2021 to USD 42.5 billion in FY2025, while equity went from USD 8.98 billion to USD 26.5 billion.

In the cash flow statement, cash from operations was USD 10.7 billion in Q2 FY2026 and USD 5.33 billion in Q1 FY2026. After capital expenditure of USD 2.93 billion in Q2, free cash flow, our calculation, was USD 7.76 billion. Quarterly cells marked D are derived from the year-to-date totals in a 10-Q. In FY2025 cash from operations of USD 16.8 billion was below net income of USD 20.6 billion. Over that year receivables rose from USD 11.0 billion to USD 17.8 billion.

Diluted EPS was USD 7.94 per share in Q2 FY2026, against USD 6.29 per share in Q2 FY2025. For FY2025 it was USD 22.95 per share, up 39.2% a year from FY2021, our calculation. Diluted shares were 899 million shares in FY2025 against 912 million shares in FY2021. The quarterly table leaves gross profit and EPS empty for Q4 FY2024 and Q4 FY2025, so nothing is said about those two quarters. Eli Lilly stock fundamentals covers the revenue run in more depth.

Income statement

Chart 1

Eli Lilly quarterly revenue, Q3 2024 to Q2 2026

USD bn · quarters ended to

Revenue by quarter, from USD 11.4 bn in Q3 2024 to USD 23.0 bn in Q2 2026.010203023.0Q32024Q4Q12025Q2Q3Q4Q12026Q2stockfactsheet.com
Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

Annual

Report an error in this table
Download CSV

Swipe for earlier periods

Table 1 Eli Lilly income statement, annual, FY2021–FY2025 (USD millions) USD millions, except per-share data (USD) and percentages · Fiscal year ends 31 December
USD mFY2025ended FY2024ended FY2023ended FY2022ended FY2021ended CAGRFY21–FY25
Revenue65,17945,04334,12428,54128,318increased 23.2%
Revenue YoY %increased 44.7%increased 32.0%increased 19.6%increased 0.8%increased 15.4%not available
Cost of revenue11,0528,4187,0826,6307,313increased 10.9%
Gross profit54,127 D36,625 R D27,042 D21,912 D21,006 Dincreased 26.7%
Gross margin %83.0%81.3% R79.2%76.8%74.2%not available
R&D13,33710,9919,3137,1916,931 Rincreased 17.8%
SG&A11,0948,5947,404 R6,4406,432increased 14.6%
Net interestnot available−605 D−312 D−269 D−314 Dnot available
Pre-tax income25,73112,6806,554 R6,8066,156increased 43.0%
Income tax5,0912,0901,314562574increased 72.6%
Net income20,64010,5905,2406,2455,582increased 38.7%
Net margin %31.7%23.5%15.4%21.9%19.7%not available
Per share
Diluted EPS (USD)22.9511.715.806.906.12increased 39.2%
Diluted shares (m)899904903905912not available
(opens in new tab)

Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

  • D Combined from line items reported in the same filing (see Methodology).
  • R Restated in Form 10-K filed ; originally reported USD 36,624 m in Form 10-K filed .
  • R Uses FY2024 gross profit as restated in Form 10-K filed (USD 36,625 m; originally reported USD 36,624 m in Form 10-K filed ).
  • R Restated in Form 10-K filed ; originally reported USD 7,026 m in Form 10-K filed .
  • R Restated in Form 10-K filed ; originally reported USD 7,403 m in Form 10-K filed .
  • D Net interest = interest income − interest expense, both from the same filing.
  • R Restated in Form 10-K filed ; originally reported USD 6,555 m in Form 10-K filed .
  • Not available

CAGR: compound annual growth rate from FY2021 to FY2025, our calculation; n/m when the endpoints differ in sign or the base is zero or negative.

Totals may not add up because of rounding.

Arrows show direction of change only, not whether a change is good or bad.

Quarterly

Report an error in this table
Download CSV

Swipe for earlier periods

Table 2 Eli Lilly income statement, quarterly, Q3 2024–Q2 2026 (USD millions) USD millions, except per-share data (USD) and percentages · Fiscal year ends 31 December
USD mQ2 2026ended Q1 2026ended Q4 2025ended Q3 2025ended Q2 2025ended Q1 2025ended Q4 2024ended Q3 2024ended
Revenue22,97419,79919,292 D17,60115,55812,72913,533 D11,439
Revenue YoY %increased 47.7%increased 55.5%increased 42.6%increased 53.9%increased 37.6%increased 45.2%increased 44.7%increased 20.4%
Cost of revenue3,2683,5773,372 D3,0082,4482,225 R2,404 D2,171
Gross profit19,706 D16,222 Dnot available14,593 D13,110 D10,504 Dnot available9,268 D
Gross margin %85.8%81.9%not available82.9%84.3%82.5%not available81.0%
R&D3,8193,5103,802 D3,4663,3362,7343,023 D2,734
SG&A3,4302,9343,131 D2,7412,7532,468 R2,425 D2,100
Net interestnot availablenot availablenot available−115 D−209 D−195 D−180 D−145 D
Pre-tax income9,2478,8508,266 D7,2326,777 R3,4565,039 D1,588
Income tax2,1521,4541,629 D1,6501,116697629 D618
Net income7,0957,3966,638 D5,5835,6612,7594,410 D970
Net margin %30.9%37.4%34.4%31.7%36.4%21.7%32.6%8.5%
Per share
Diluted EPS (USD)7.948.26not available6.216.293.06not available1.07
Diluted shares (m)894896not available899900901not available905
(opens in new tab)

Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

  • D Fourth quarter derived as the fiscal year minus the nine-month year-to-date total.
  • R Restated in Form 10-Q filed ; originally reported USD 2,224 m in Form 10-Q filed .
  • D Combined from line items reported in the same filing (see Methodology).
  • R Restated in Form 10-Q filed ; originally reported USD 2,469 m in Form 10-Q filed .
  • D Net interest = interest income − interest expense, both from the same filing.
  • R Restated in Form 10-Q filed ; originally reported USD 6,776 m in Form 10-Q filed .
  • Not available

Totals may not add up because of rounding.

Arrows show direction of change only, not whether a change is good or bad.

Balance sheet

Annual

Report an error in this table
Download CSV

Swipe for earlier periods

Table 3 Eli Lilly assets, annual, FY2021–FY2025 (USD millions) USD millions
USD mFY2025at FY2024at FY2023at FY2022at FY2021at
Cash and short-term investments7,2683,423 D2,928 D2,212 D3,909 D
Receivables17,76011,0069,0916,8966,673
Inventory13,7447,5895,7734,3103,886
Total current assets55,62932,74025,72718,03518,452
PP&E (net)24,67517,10212,91410,1448,985
Goodwill and intangibles12,419 D11,936 R D11,846 D11,280 D11,584 D
Total assets112,47678,71564,00649,49048,806
(opens in new tab)

Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

  • D Cash and cash equivalents plus the short-term investments, current marketable securities or current debt securities the filing tags, from the same filing.
  • D Goodwill plus the intangible assets the filing reports under the standard intangible-asset tags or the components our mapping lists for the company, from the same filing. Intangible assets a company shows on separate balance sheet lines under other tags, such as licences, may not be included, so for some companies this line is goodwill alone; the lines included can change when the company changes its balance sheet.
  • R Restated in Form 10-K filed ; originally reported USD 11,937 m in Form 10-K filed .

Totals may not add up because of rounding.

Report an error in this table
Download CSV

Swipe for earlier periods

Table 4 Eli Lilly liabilities and shareholders' equity, annual, FY2021–FY2025 (USD millions) USD millions · net cash shown as a negative net debt
USD mFY2025at FY2024at FY2023at FY2022at FY2021at
Current liabilities35,22828,376 R27,29317,13815,053
Total debt42,503 D33,644 D25,225 D16,239 D16,885 D
Total liabilitiesnot available64,443 D53,143 D38,714 D39,651 D
Shareholders' equity26,53514,272 R10,77210,6508,979
Net debt / (net cash)35,235 D30,221 D22,298 D14,027 D12,976 D
(opens in new tab)

Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

  • R Restated in Form 10-K filed ; originally reported USD 28,377 m in Form 10-K filed .
  • D Total debt = short-term debt + long-term debt, from the same filing.
  • D Total liabilities = total liabilities and equity − total equity, from the same filing.
  • R Restated in Form 10-K filed ; originally reported USD 14,192 m in Form 10-K filed .
  • D Net debt = total debt minus cash and short-term investments; a negative value is net cash.
  • Not available

Totals may not add up because of rounding.

Quarterly

Report an error in this table
Download CSV

Swipe for earlier periods

Table 5 Eli Lilly assets, quarterly, Q3 2024–Q2 2026 (USD millions) USD millions
USD mQ2 2026at Q1 2026at Q4 2025at Q3 2025at Q2 2025at Q1 2025at Q4 2024at Q3 2024at
Cash and short-term investments8,9505,2827,2689,914 D3,546 D3,221 D3,423 D3,518 D
Receivables20,08318,42917,76016,10714,17012,03711,00610,295
Inventory16,79314,52913,74412,18011,0149,3117,5897,460
Total current assets64,67254,83555,62962,07149,85441,26132,74031,415
PP&E (net)29,28626,54024,67522,31620,53018,47417,10216,172
Goodwill and intangibles26,959 D13,504 D12,419 D12,345 D11,679 D11,783 D11,936 R D12,306 D
Total assets142,283116,576112,476114,935100,92389,38978,71575,607
(opens in new tab)

Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

  • D Cash and cash equivalents plus the short-term investments, current marketable securities or current debt securities the filing tags, from the same filing.
  • D Goodwill plus the intangible assets the filing reports under the standard intangible-asset tags or the components our mapping lists for the company, from the same filing. Intangible assets a company shows on separate balance sheet lines under other tags, such as licences, may not be included, so for some companies this line is goodwill alone; the lines included can change when the company changes its balance sheet.
  • R Restated in Form 10-K filed ; originally reported USD 11,937 m in Form 10-K filed .

Totals may not add up because of rounding.

Report an error in this table
Download CSV

Swipe for earlier periods

Table 6 Eli Lilly liabilities and shareholders' equity, quarterly, Q3 2024–Q2 2026 (USD millions) USD millions · net cash shown as a negative net debt
USD mQ2 2026at Q1 2026at Q4 2025at Q3 2025at Q2 2025at Q1 2025at Q4 2024at Q3 2024at
Current liabilities47,74136,63435,22840,14139,02030,06828,376 R24,674
Total debt54,908 D43,370 D42,503 D42,507 D39,904 D38,516 D33,644 D31,120 D
Total liabilitiesnot availablenot availablenot available91,085 D82,574 D73,542 D64,443 D61,286 D
Shareholders' equity33,87931,19826,53523,79318,27315,76514,272 R14,240
Net debt / (net cash)45,958 D38,088 D35,235 D32,593 D36,358 D35,295 D30,221 D27,601 D
(opens in new tab)

Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

  • R Restated in Form 10-K filed ; originally reported USD 28,377 m in Form 10-K filed .
  • D Total debt = short-term debt + long-term debt, from the same filing.
  • D Total liabilities = total liabilities and equity − total equity, from the same filing.
  • R Restated in Form 10-K filed ; originally reported USD 14,192 m in Form 10-K filed .
  • D Net debt = total debt minus cash and short-term investments; a negative value is net cash.
  • Not available

Totals may not add up because of rounding.

Cash flow

Chart 2

Eli Lilly quarterly free cash flow, Q3 2024 to Q2 2026

USD bn · quarters ended to

Free cash flow by quarter, from USD 2.36 bn in Q3 2024 to USD 7.76 bn in Q2 2026.024687.8Q32024Q4Q12025Q2Q3Q4Q12026Q2stockfactsheet.com
Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

Annual

Report an error in this table
Download CSV

Swipe for earlier periods

Table 7 Eli Lilly cash flow, annual, FY2021–FY2025 (USD millions) USD millions · outflows shown with a minus sign
USD mFY2025ended FY2024ended FY2023ended FY2022ended FY2021ended
Cash from operations16,8138,8184,2407,586 R7,366 R
Capital expenditure−7,841−5,058−3,448−1,854−1,310
Free cash flow8,972 D3,760 D793 D5,731 R D6,056 R D
Dividends paid−5,384−4,680−4,069−3,536−3,087
Share buybacks−4,108−2,500−750−1,500−1,250
Cash from investing−10,972−9,302−7,153−3,763 R−2,868 R
Cash from financing−2,2131,2303,496−5,407−4,131
(opens in new tab)

Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

  • R Restated in Form 10-K filed ; originally reported USD 7,084 m in Form 10-K filed .
  • R Restated in Form 10-K filed ; originally reported USD 7,261 m in Form 10-K filed .
  • D Free cash flow = cash from operations minus capital expenditure.
  • R Uses FY2022 cash from operations as restated in Form 10-K filed (USD 7,586 m; originally reported USD 7,084 m in Form 10-K filed ).
  • R Uses FY2021 cash from operations as restated in Form 10-K filed (USD 7,366 m; originally reported USD 7,261 m in Form 10-K filed ).
  • R Restated in Form 10-K filed ; originally reported USD −3,262 m in Form 10-K filed .
  • R Restated in Form 10-K filed ; originally reported USD −2,762 m in Form 10-K filed .

Totals may not add up because of rounding.

Quarterly

Report an error in this table
Download CSV

Swipe for earlier periods

Table 8 Eli Lilly cash flow, quarterly, Q3 2024–Q2 2026 (USD millions) USD millions · outflows shown with a minus sign
USD mQ2 2026ended Q1 2026ended Q4 2025ended Q3 2025ended Q2 2025ended Q1 2025ended Q4 2024ended Q3 2024ended
Cash from operations10,690 D5,3333,225 D8,836 D3,087 D1,6662,474 D3,712 D
Capital expenditure−2,933 D−2,326−2,547 D−2,088 D−1,697 D−1,510−1,496 D−1,351 D
Free cash flow7,757 D3,007 D678 D6,748 D1,390 D156 D978 D2,361 D
Dividends paid−1,546 D−1,548−1,346 D−1,345 D−1,347 D−1,346−1,168 D−1,171 D
Share buybacks−1,601 D−2,356−1,508 D−708 D−692 D−1,200−2,054 D−446 D
Cash from investing−15,396 D−3,916−2,802 D−2,983 D−1,834 R D−3,353 R−1,921 D−4,005 D
Cash from financing8,426 D−3,470−2,879 D531 D−1,245 D1,380−225 D211 D
(opens in new tab)

Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

  • D Quarter derived from year-to-date totals: the six- or nine-month figure minus the earlier quarters.
  • D Fourth quarter derived as the fiscal year minus the nine-month year-to-date total.
  • D Free cash flow = cash from operations minus capital expenditure.
  • R Restated in Form 10-Q filed ; originally reported USD −3,352 m in Form 10-Q filed .
  • R Restated

Totals may not add up because of rounding.

Per share and dividends

Report an error in this table
Download CSV

Swipe for earlier periods

Table 9 Eli Lilly per-share data and dividends, annual, FY2021–FY2025 USD per share, split-adjusted · shares in millions
USDFY2025ended FY2024ended FY2023ended FY2022ended FY2021ended
Basic EPS (USD)23.0011.765.826.936.15
Diluted EPS (USD)22.9511.715.806.906.12
Dividends declared per share (USD)6.235.404.694.073.53
Diluted shares (m)899904903905912
FCF cover (×)1.7×0.8×0.2×1.6× R2.0× R
(opens in new tab)

Source: Eli Lilly Forms 10-Q and 10-K, SEC EDGAR Data as of

  • R Uses FY2022 cash from operations as restated in Form 10-K filed (USD 7,586 m; originally reported USD 7,084 m in Form 10-K filed ).
  • R Uses FY2021 cash from operations as restated in Form 10-K filed (USD 7,366 m; originally reported USD 7,261 m in Form 10-K filed ).

Notes on these figures

  • R Restated
    • Restated in Form 10-K filed ; originally reported USD 36,624 m in Form 10-K filed .
    • Uses FY2024 gross profit as restated in Form 10-K filed (USD 36,625 m; originally reported USD 36,624 m in Form 10-K filed ).
    • Restated in Form 10-K filed ; originally reported USD 7,026 m in Form 10-K filed .
    • Restated in Form 10-K filed ; originally reported USD 7,403 m in Form 10-K filed .
    • Restated in Form 10-K filed ; originally reported USD 6,555 m in Form 10-K filed .
    • Restated in Form 10-Q filed ; originally reported USD 2,224 m in Form 10-Q filed .
    • Restated in Form 10-Q filed ; originally reported USD 2,469 m in Form 10-Q filed .
    • Restated in Form 10-Q filed ; originally reported USD 6,776 m in Form 10-Q filed .
    • Restated in Form 10-K filed ; originally reported USD 11,937 m in Form 10-K filed .
    • Restated in Form 10-K filed ; originally reported USD 28,377 m in Form 10-K filed .
    • Restated in Form 10-K filed ; originally reported USD 14,192 m in Form 10-K filed .
    • Restated in Form 10-K filed ; originally reported USD 7,084 m in Form 10-K filed .
    • Restated in Form 10-K filed ; originally reported USD 7,261 m in Form 10-K filed .
    • Uses FY2022 cash from operations as restated in Form 10-K filed (USD 7,586 m; originally reported USD 7,084 m in Form 10-K filed ).
    • Uses FY2021 cash from operations as restated in Form 10-K filed (USD 7,366 m; originally reported USD 7,261 m in Form 10-K filed ).
    • Restated in Form 10-K filed ; originally reported USD −3,262 m in Form 10-K filed .
    • Restated in Form 10-K filed ; originally reported USD −2,762 m in Form 10-K filed .
    • Restated in Form 10-Q filed ; originally reported USD −3,352 m in Form 10-Q filed .
  • D Derived by StockFactsheet
    • Combined from line items reported in the same filing (see Methodology).
    • Net interest = interest income − interest expense, both from the same filing.
    • Fourth quarter derived as the fiscal year minus the nine-month year-to-date total.
    • Cash and cash equivalents plus the short-term investments, current marketable securities or current debt securities the filing tags, from the same filing.
    • Goodwill plus the intangible assets the filing reports under the standard intangible-asset tags or the components our mapping lists for the company, from the same filing. Intangible assets a company shows on separate balance sheet lines under other tags, such as licences, may not be included, so for some companies this line is goodwill alone; the lines included can change when the company changes its balance sheet.
    • Total debt = short-term debt + long-term debt, from the same filing.
    • Total liabilities = total liabilities and equity − total equity, from the same filing.
    • Net debt = total debt minus cash and short-term investments; a negative value is net cash.
    • Free cash flow = cash from operations minus capital expenditure.
    • Quarter derived from year-to-date totals: the six- or nine-month figure minus the earlier quarters.
  • Template: standard statement set (not bank or insurer).
  • Arrows show direction of change only, not whether a change is good or bad.

How we got these numbers

Every figure comes from Eli Lilly's Forms 10-Q and 10-K as filed with the SEC. Derived values are marked D and explained below.

Full method for this page
Source documents
Forms 10-Q (Q3 2024 to Q2 2026) and 10-K (FY2021 to FY2025)
Period covered
8 quarters and 5 fiscal years
Calculations
TTM = sum of the last 4 quarters. Q4 = fiscal year minus the nine-month YTD. Margins = line item ÷ revenue. FCF = cash from operations − capital expenditure. CAGR = compound annual growth across the annual table.
Restatements
FY2024 gross profit, an input of the FY2024 ratio, was restated in Form 10-K filed (originally USD 36,624 m). FY2022 cash from operations, an input of the FY2022 ratio, was restated in Form 10-K filed (originally USD 7,084 m). FY2021 cash from operations, an input of the FY2021 ratio, was restated in Form 10-K filed (originally USD 7,261 m). Restated figures carry the R marker; its footnote gives the originally reported value.
Comparator
None: this page shows the company's own figures only.
Currency
As reported (USD); no FX conversion.
Read the full methodology

CSV downloads

One file per statement, with the annual and quarterly figures on this page in full units.

Sources and data

Data as of Figures are as reported in the filings below. Derived figures are our calculations (see Methodology).

(opens in new tab)
  1. [1] Filing Form 10-Q, quarter ended 30 Jun 2026 Eli Lilly and Company · · sec.gov
  2. [2] Filing Form 10-Q, quarter ended 31 Mar 2026 Eli Lilly and Company · · sec.gov
  3. [3] Filing Form 10-K, fiscal year ended 31 Dec 2025 Eli Lilly and Company · · sec.gov
  4. [4] Filing Form 10-Q, quarter ended 30 Sep 2025 Eli Lilly and Company · · sec.gov
  5. [5] Filing Form 10-Q, quarter ended 30 Jun 2025 Eli Lilly and Company · · sec.gov
  6. [6] Filing Form 10-Q, quarter ended 31 Mar 2025 Eli Lilly and Company · · sec.gov
  7. [7] Filing Form 10-K, fiscal year ended 31 Dec 2024 Eli Lilly and Company · · sec.gov
  8. [8] Filing Form 10-Q, quarter ended 30 Sep 2024 Eli Lilly and Company · · sec.gov
  9. [9] Filing Form 10-K, fiscal year ended 31 Dec 2023 Eli Lilly and Company · · sec.gov
  10. [10] Filing Form 10-K, fiscal year ended 31 Dec 2022 Eli Lilly and Company · · sec.gov
  11. [11] Filing Form 10-K, fiscal year ended 31 Dec 2021 Eli Lilly and Company · · sec.gov
  12. [12] Filing Form 10-Q, quarter ended 30 Jun 2024 Eli Lilly and Company · · sec.gov
  13. [13] Filing Form 10-Q, quarter ended 31 Mar 2024 Eli Lilly and Company · · sec.gov
  14. [14] Filing Form 10-Q, quarter ended 30 Sep 2023 Eli Lilly and Company · · sec.gov
  15. [15] Filing Form 10-K, fiscal year ended 31 Dec 2020 Eli Lilly and Company · · sec.gov
  16. [16] Our dataset StockFactsheet fundamentals dataset, extracted from SEC EDGAR XBRL on ; derived values (Q4, TTM, free cash flow, net debt, margins, growth rates and ratios) are explained in Methodology.

Spotted an error? Report it Corrections log Methodology

Cite this page

StockFactsheet (2026). "Eli Lilly (LLY) financial statements: income, balance sheet and cash flow." Signed off by OffScriptBySami. Updated ; data as of . https://stockfactsheet.com/stocks/lly/financials/

Not investment advice

For information only. StockFactsheet does not recommend buying, selling or holding any security. Figures can contain errors; always check the original filings. Full disclaimer

Author and editor

Signed off by OffScriptBySami on · How pages are checked

StockFactsheet is not a licensed investment adviser, broker or dealer, and does not give personal recommendations.

How this page was made
  1. Data imported (SEC EDGAR, )
  2. Drafted from our dataset only
  3. Automated checks and review steps passed ()
  4. Signed off and published by OffScriptBySami (, GST)

Update history

  1. Published First published version.